Showing 37,721 - 37,740 results of 103,778 for search '(( e point decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.86s Refine Results
  1. 37721

    Model-predicted effect of once a day administration of 1000 mg of acetazolamide. by Nicholas Heming (510208)

    Published 2014
    “…Minute ventilation is predicted to increase by more than 0.75 l min<sup>−1</sup> in 65% of patients (A) and PaCO<sub>2</sub> is predicted to decrease by 5 mmHg in 45% of patients (B) supported by pressure support ventilation treated by 1000 mg day<sup>−1</sup> of acetazolamide. …”
  2. 37722

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  3. 37723

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  4. 37724

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  5. 37725

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  6. 37726

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  7. 37727

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  8. 37728

    Calorie restriction leads to telomere maintenance and/or elongation with time in a percentage of mice. by Elsa Vera (93180)

    Published 2013
    “…<p>(A, C and E) The behavior of mean telomere length was classified in two different profiles (“Decrease” and “Increase or Maintenance”) at different times of diet (1–22 months of diet, 5–22 months of diet and 9–22 months of diet; A, C and E, respectively) in the indicated groups. …”
  9. 37729
  10. 37730
  11. 37731
  12. 37732

    Treatment of 2D cell culture by a γ-secretase inhibitor. by Han-Kyu Lee (3184848)

    Published 2016
    “…B. Aβ42 levels were significantly decreased in all 5 AD subjects after treatment with the γ-secretase inhibitor at all doses tested. …”
  13. 37733

    DataSheet_1_The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study.docx by Shanhai Ou (9957037)

    Published 2022
    “…The nAbs of plasma samples (collected between 2-6 weeks after the 3<sup>rd</sup> dose) from triple-vaccinated donors (n=94) showed a geometric mean titer of 145.3 (95% CI: 117.2 to 180.1) against the ancestral B.1, slightly reduced by 1.7-fold against Delta variant, but markedly decreased by 4-6 fold in neutralizing Omicron variants, including the sub-lineages of BA.1 (5.6-fold), BA.1.1 (6.0-fold), BA.2 (4.2-fold), B.2.12.1 (6.2-fold) and BA.4/5 (6.5-fold).…”
  14. 37734
  15. 37735

    Baseline characteristics. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  16. 37736

    Subgroup analyses for the primary outcome. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  17. 37737

    Outcomes. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  18. 37738

    Trial profile. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  19. 37739

    Utilizing reduction in spheroid counts and/or total nuclear intensity to determine toxic effects of compounds. by Pranjali Beri (14945400)

    Published 2023
    “…They are indicated appropriately in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0287809#pone.0287809.g004" target="_blank">Fig 4</a>. …”
  20. 37740